查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1880627

大环内酯类抗生素市场规模、占有率、成长及全球产业分析：依类型、应用和地区划分的洞察与预测（2024-2032 年）

Macrolide Antibiotics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 请询问到货日

价格

大环内酯类抗生素市场成长驱动因子

受细菌感染日益普遍以及对先进抗菌疗法需求不断增长的推动，全球大环内酯类抗生素市场持续稳步增长。根据最新的产业评估，预计到 2024 年，该市场规模将达到 59.6 亿美元，这主要得益于大环内酯类抗生素在呼吸道感染、皮肤感染和性传染感染治疗中的高处方量和广泛应用。到 2025 年，预计该市场规模将扩大至 61.6 亿美元，这主要得益于对生物利用度更高、抗药性更低的抗生素的需求不断增长。预计到2032年，大环内酯类抗生素市场规模将达到80.6亿美元，2025年至2032年的复合年增长率（CAGR）为3.9%。北美将在2024年占市场主导地位，市占率将达到28.3亿美元（47.48%）。这主要得益于北美强大的医疗基础设施、较高的抗生素消费量以及持续的药物研发活动。

大环内酯类抗生素透过与50S核醣体亚基可逆结合，抑制细菌蛋白质合成，进而发挥抗菌作用。新一代大环内酯类抗生素，如阿奇霉素和克拉霉素，具有广谱抗菌、更优的药物动力学特性和更高的安全性，其临床应用日益广泛。这些药物发挥着至关重要的作用，尤其是在儿科护理中，因为在儿科护理中，不建议使用氟喹诺酮类等替代药物。

市场推动因素

市场成长的主要推动因素是全球细菌感染（特别是呼吸道感染、性传染感染和皮肤感染）的增加趋势。根据世界卫生组织（2024年7月）的数据，15至49岁成年人中报告了8240万例新的淋病病例，这显着增加了对阿奇霉素和类似大环内酯类药物的需求。处方量的增加也推动了市场的发展势头，2023年美国零售药局每1,000人约配发105份大环内酯类药物。

新型大环内酯类药物的改良配方也是推动市场成长的因素。 2023年10月，美国FDA核准Fathom Pharmaceuticals公司的VOQUEZNA TRIPLE PAK和DUAL PAK用于治疗幽门螺旋桿菌感染，将推动含克拉霉素治疗方案的广泛应用。

市场限制因子

主要阻碍因素之一是与生产缺陷、无菌问题和标籤问题相关的召回事件日益增多。这些召回事件损害了品牌形象，削弱了消费者信心。例如，2025年2月，新加坡卫生科学局因无菌问题召回了克拉霉素Evert 500mg。同样，英国药品和保健产品监管局（MHRA）于2023年12月宣布召回多种克拉霉素片剂。这些反覆发生的事件给监管和市场推广带来了挑战。

市场机会

在细菌感染率较高的亚洲、非洲和拉丁美洲，随着各国政府加强对本土药物研发的支持力度，巨大的市场机会正在涌现。一个显着的例子是印度在生物製品资讯研究援助委员会 (BIRAC) 的支持下于 2024 年 11 月推出的萘菲霉素 (nafithromycin)。该药物用于治疗社区型细菌性肺炎 (CABP)。国产新药的上市将提高药物的可近性和可负担性，从而扩大发展中地区的市场潜力。

区域展望

北美

预计到 2024 年，北美市场规模将达到 28.3 亿美元，由于其高发病率、强大的研发投入以及在对抗抗生素抗药性方面的大量投资，北美仍然是全球领先市场。美国继续主导该地区的需求，这得益于联邦政府的拨款，例如美国国家过敏症和传染病研究所 (NIAID) 于 2024 年 5 月拨款 270 万美元用于大环内酯类抗药性研究。

欧洲

欧洲占第二大市场占有率，主要得益于广谱抗生素消费量的成长。区域研究表明，2019年至2021年间，抗生素使用量激增，推动了用于治疗呼吸道和胃肠道感染的大环内酯类抗生素的需求。

亚太地区

预计到2032年，亚太地区将维持最高的复合年增长率，这主要得益于医疗保健服务的改善、疾病负担沉重以及人口的快速增长。例如，世界卫生组织于2024年预先批准孟加拉国的Rockville阿奇霉素500毫克，这将进一步巩固区域市场的成长。

拉丁美洲、中东/非洲

由于细菌感染病例的增加和国际合作的加强，这些地区的需求正在温和增长。例如，辉瑞公司于 2022 年 6 月向世界卫生组织捐赠了阿奇霉素，加强了沙眼流行国家获得这种抗生素的机会。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场推动因素
  • 市场阻碍因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 2024年主要国家和地区主要疾病盛行率
  • 主要公司产品线分析
  • 主要产业趋势（併购、合作等）
  • 主要国家和地区的监管和报销情况

第五章：全球大环内酯类抗生素市场分析洞察与预测 (2019-2032)

  • 市场分析、洞察与预测 - 依产品划分
    • 阿奇霉素
    • 克拉霉素
    • 奥利霉素
    • 红霉素
    • 其他
  • 市场分析、洞察与预测 - 依疾病划分
    • 呼吸道感染
    • 皮肤感染
    • 性传染感染 (STI)
    • 其他
  • 市场分析、洞察与预测 - 依给药途径划分
    • 口服
    • 注射
    • 其他
  • 市场分析、洞察与预测 - 依年龄划分组别
    • 成人
    • 儿科
  • 市场分析、洞察与预测 - 依分销管道划分
    • 医院药房
    • 药局和零售药房
    • 线上药房
  • 市场分析、洞察与预测 - 依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美大环内酯类抗生素市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲大环内酯类抗生素市场分析、洞察与预测2019-2032

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚半岛
    • 欧洲其他地区

第八章：亚太地区大环内酯类抗生素市场分析、洞察与预测，2019-2032

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲大环内酯类抗生素市场分析、洞察与预测，2019-2032

  • 依国家/地区
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章 中东和非洲大环内酯类抗生素市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 海湾合作委员会 (GCC)
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析（2024）
  • 公司简介
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Crescent Pharma Ltd.
    • Wellona Pharma
    • Zydus Group
    • Merck &Co., Inc.
    • Alkem
    • Azurity Pharmaceuticals, Inc.
    • Lupin
    • Sun Pharmaceutical Industries Ltd.
Product Code: FBI113847

Growth Factors of macrolide antibiotics Market

The global macrolide antibiotics market continues to grow steadily as the burden of bacterial infections rises worldwide and the need for advanced antimicrobial therapies accelerates. According to the latest industry assessment, the market size reached USD 5.96 billion in 2024, driven by high prescription volumes and widespread utilization of macrolides for respiratory, skin, and sexually transmitted infections. In 2025, the market is expected to rise to USD 6.16 billion, supported by increasing demand for antibiotics with improved bioavailability and reduced microbial resistance. By 2032, the macrolide antibiotics market is projected to reach USD 8.06 billion, expanding at a CAGR of 3.9% from 2025-2032. In 2024, North America dominated the market with a 47.48% share, valued at USD 2.83 billion, attributed to strong healthcare infrastructure, high antibiotic consumption, and ongoing drug development activities.

Macrolide antibiotics function by inhibiting bacterial protein synthesis through reversible binding to the 50S ribosomal subunit. With their broad-spectrum antimicrobial capabilities, enhanced pharmacokinetics, and improved safety profile, next-generation macrolides such as azithromycin and clarithromycin continue to gain strong clinical adoption. They are especially vital in pediatric care, where alternatives such as fluoroquinolones are not recommended.

Market Drivers

A key driver of market growth is the increasing global prevalence of bacterial infections, particularly respiratory infections, sexually transmitted diseases (STIs), and skin infections. According to WHO (July 2024), 82.4 million new gonorrhea cases were reported among adults aged 15-49 years, significantly increasing demand for azithromycin and similar macrolides. Rising prescription volumes further strengthen market momentum, with U.S. retail pharmacies dispensing around 105 macrolide prescriptions per 1,000 population in 2023.

New macrolide drug reformulations are also fueling growth. The U.S. FDA approval in October 2023 for Phathom Pharmaceuticals' VOQUEZNA TRIPLE PAK and DUAL PAK for H. pylori infection has enhanced adoption of clarithromycin-inclusive treatment regimens.

Market Restraints

One of the major restraints is the growing number of product recalls linked to manufacturing defects, sterility issues, and labeling problems. Such recalls damage brand reputation and hinder consumer trust. For example, in February 2025, Singapore's Health Sciences Authority recalled Clarithromycin Eberth 500 mg due to failed sterility tests. Similarly, the U.K.'s MHRA issued multiple recalls for clarithromycin tablets in December 2023. These recurring incidents create regulatory and market-adoption challenges.

Market Opportunities

Significant opportunities are emerging across Asia, Africa, and Latin America, where bacterial infection rates remain high, and governments increasingly support indigenous drug development. A notable example includes India's launch of Nafithromycin in November 2024, developed with BIRAC support to target community-acquired bacterial pneumonia (CABP). New domestic drug launches enhance accessibility and affordability, expanding market potential in developing regions.

Regional Outlook

North America

With a market value of USD 2.83 billion in 2024, North America remains the global leader due to high disease prevalence, strong R&D initiatives, and significant investment in combating antibiotic resistance. The U.S. continues to dominate regional demand, supported by federal grants such as the USD 2.7 million NIAID funding in May 2024 for macrolide-resistance research.

Europe

Europe holds the second-largest share, driven by increased consumption of broad-spectrum antibiotics. Regional studies show a surge in antibiotic use between 2019-2021, boosting demand for macrolides used in respiratory and gastrointestinal infections.

Asia Pacific

Asia Pacific is anticipated to record the highest CAGR through 2032, supported by improving healthcare access, high disease burden, and rapid population growth. Advancements such as WHO prequalification of Bangladesh-based Rockville's azithromycin 500 mg in 2024 further strengthen regional market progress.

Latin America & Middle East/Africa

These regions show moderate but expanding demand, driven by rising bacterial infections and international collaborations. For instance, Pfizer's donation of Zithromax to WHO in June 2022 strengthens antibiotic access in trachoma-endemic nations.

Competitive Landscape

The market is semi-consolidated with leading companies such as Pfizer, Teva Pharmaceutical Industries, Merck & Co., Aurobindo Pharma, Lupin, Zydus Group, and Sun Pharma. Key strategies include generic launches, investments in R&D, and partnerships with regulatory agencies. Ongoing developments-such as Aurobindo's U.S. FDA approval for azithromycin and Alembic's clarithromycin ANDA approval-continue to shape the competitive environment.

Conclusion

Supported by rising infection rates, expanded drug development, and strong adoption across pediatric and adult populations, the macrolide antibiotics market is expected to grow from USD 5.96 billion in 2024 to USD 8.06 billion by 2032. Continuous research, international collaborations, and improved drug formulations will remain key growth accelerators throughout the forecast period.

Segmentation By Product

  • Azithromycin
  • Clarithromycin
  • Oleandomycin
  • Erythromycin
  • Others

By Disease Indication

  • Respiratory Infections
  • Skin Infections
  • Sexually Transmitted Diseases (STIs)
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Others

By Age Group

  • Adults
  • Pediatrics

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Product, Disease Indication, Route of Administration, Age Group, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Product, Disease Indication, Route of Administration, Age Group, Distribution Channel, and Country/sub-region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product, Disease Indication, Route of Administration, Age Group, Distribution Channel, and Country/sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product, Disease Indication, Route of Administration, Age Group, Distribution Channel, and Country/sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product, Disease Indication, Route of Administration, Age Group, Distribution Channel, and Country/sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Diseases- by Key Countries/Regions, 2024
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.4. Regulatory & Reimbursement Scenarios, By Key Countries/ Regions

5. Global Macrolide Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Azithromycin
    • 5.1.2. Clarithromycin
    • 5.1.3. Oleandomycin
    • 5.1.4. Erythromycin
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.2.1. Respiratory Infections
    • 5.2.2. Skin Infections
    • 5.2.3. Sexually Transmitted Diseases (STIs)
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Age Group
    • 5.4.1. Adults
    • 5.4.2. Pediatrics
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital Pharmacies
    • 5.5.2. Drug Stores & Retail Pharmacies
    • 5.5.3. Online Pharmacies
  • 5.6. Market Analysis, Insights and Forecast - Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Macrolide Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Azithromycin
    • 6.1.2. Clarithromycin
    • 6.1.3. Oleandomycin
    • 6.1.4. Erythromycin
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 6.2.1. Respiratory Infections
    • 6.2.2. Skin Infections
    • 6.2.3. Sexually Transmitted Diseases (STIs)
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Age Group
    • 6.4.1. Adults
    • 6.4.2. Pediatrics
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital Pharmacies
    • 6.5.2. Drug Stores & Retail Pharmacies
    • 6.5.3. Online Pharmacies
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Macrolide Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Azithromycin
    • 7.1.2. Clarithromycin
    • 7.1.3. Oleandomycin
    • 7.1.4. Erythromycin
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 7.2.1. Respiratory Infections
    • 7.2.2. Skin Infections
    • 7.2.3. Sexually Transmitted Diseases (STIs)
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Age Group
    • 7.4.1. Adults
    • 7.4.2. Pediatrics
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital Pharmacies
    • 7.5.2. Drug Stores & Retail Pharmacies
    • 7.5.3. Online Pharmacies
  • 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.6.1. Germany
    • 7.6.2. U.K.
    • 7.6.3. France
    • 7.6.4. Italy
    • 7.6.5. Spain
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Macrolide Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Azithromycin
    • 8.1.2. Clarithromycin
    • 8.1.3. Oleandomycin
    • 8.1.4. Erythromycin
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 8.2.1. Respiratory Infections
    • 8.2.2. Skin Infections
    • 8.2.3. Sexually Transmitted Diseases (STIs)
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Age Group
    • 8.4.1. Adults
    • 8.4.2. Pediatrics
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital Pharmacies
    • 8.5.2. Drug Stores & Retail Pharmacies
    • 8.5.3. Online Pharmacies
  • 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.6.1. China
    • 8.6.2. Japan
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. Southeast Asia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Macrolide Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Azithromycin
    • 9.1.2. Clarithromycin
    • 9.1.3. Oleandomycin
    • 9.1.4. Erythromycin
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 9.2.1. Respiratory Infections
    • 9.2.2. Skin Infections
    • 9.2.3. Sexually Transmitted Diseases (STIs)
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Age Group
    • 9.4.1. Adults
    • 9.4.2. Pediatrics
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital Pharmacies
    • 9.5.2. Drug Stores & Retail Pharmacies
    • 9.5.3. Online Pharmacies
  • 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Macrolide Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Azithromycin
    • 10.1.2. Clarithromycin
    • 10.1.3. Oleandomycin
    • 10.1.4. Erythromycin
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 10.2.1. Respiratory Infections
    • 10.2.2. Skin Infections
    • 10.2.3. Sexually Transmitted Diseases (STIs)
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Age Group
    • 10.4.1. Adults
    • 10.4.2. Pediatrics
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Drug Stores & Retail Pharmacies
    • 10.5.3. Online Pharmacies
  • 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. Pfizer Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Teva Pharmaceutical Industries Ltd.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Crescent Pharma Ltd.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Wellona Pharma
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Zydus Group
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Merck & Co., Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Alkem
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Azurity Pharmaceuticals, Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Lupin
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Sun Pharmaceutical Industries Ltd.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 2: Global Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2033
  • Table 3: Global Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2034
  • Table 4: Global Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Age Group, 2019-2034
  • Table 5: Global Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 6: Global Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 7: Global Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 8: North America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2033
  • Table 9: North America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2034
  • Table10: North America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Age Group, 2019-2034
  • Table 11: North America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 12: North America Macrolide Antibiotics Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 13: Europe Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 14: Europe Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2033
  • Table 15: Europe Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2034
  • Table 16: Europe Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Age Group, 2019-2034
  • Table 17: Europe Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 18: Europe Macrolide Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 19: Asia Pacific Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 20: Asia Pacific Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2033
  • Table 21: Asia Pacific Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2034
  • Table 22: Asia Pacific Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Age Group, 2019-2034
  • Table 23: Asia Pacific Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 24: Asia Pacific Macrolide Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 25: Latin America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 26: Latin America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2033
  • Table 27: Latin America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2034
  • Table 28: Latin America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Age Group, 2019-2034
  • Table 29: Latin America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 30: Latin America Macrolide Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 31: Middle East & Africa Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 32: Middle East & Africa Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2033
  • Table 33: Middle East & Africa Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2034
  • Table 34: Middle East & Africa Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Age Group, 2019-2034
  • Table 35: Middle East & Africa Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 36: Middle East & Africa Macrolide Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Macrolide Antibiotics Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Macrolide Antibiotics Market Value Share (%), by Product, 2024 & 2032
  • Figure 3: Global Macrolide Antibiotics Market Value Share (%), by Disease Indication, 2024 & 2032
  • Figure 4: Global Macrolide Antibiotics Market Value Share (%), by Route of Administration, 2024 & 2032
  • Figure 5: Global Macrolide Antibiotics Market Value Share (%), by Age Group, 2024 & 2032
  • Figure 6: Global Macrolide Antibiotics Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 7: Global Macrolide Antibiotics Market Value Share (%), by Region, 2024 & 2032
  • Figure 8: North America Macrolide Antibiotics Market Value (USD billion), by Product, 2024 & 2032
  • Figure 9: North America Macrolide Antibiotics Market Value Share (%), by Product, 2024
  • Figure 10: North America Macrolide Antibiotics Market Value (USD billion), by Disease Indication, 2024 & 2032
  • Figure 11: North America Macrolide Antibiotics Market Value Share (%), by Disease Indication, 2024
  • Figure 12: North America Macrolide Antibiotics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 13: North America Macrolide Antibiotics Market Value Share (%), by Route of Administration, 2024

2024 & 2032

  • Figure 14: North America Macrolide Antibiotics Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 15: North America Macrolide Antibiotics Market Value Share (%), by Age Group, 2024
  • Figure 16: North America Macrolide Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 17: North America Macrolide Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 18: North America Macrolide Antibiotics Market Value (USD billion), By Country, 2024 & 2032
  • Figure 19: North America Macrolide Antibiotics Market Value Share (%), By Country, 2024
  • Figure 20: Europe Macrolide Antibiotics Market Value (USD billion), by Product, 2024 & 2032
  • Figure 21: Europe Macrolide Antibiotics Market Value Share (%), by Product, 2024
  • Figure 22: Europe Macrolide Antibiotics Market Value (USD billion), by Disease Indication, 2024 & 2032
  • Figure 23: Europe Macrolide Antibiotics Market Value Share (%), by Disease Indication, 2024
  • Figure 24: Europe Macrolide Antibiotics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 25: Europe Macrolide Antibiotics Market Value Share (%), by Route of Administration, 2024

2024 & 2032

  • Figure 26: Europe Macrolide Antibiotics Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 27: Europe Macrolide Antibiotics Market Value Share (%), by Age Group, 2024
  • Figure 28: Europe Macrolide Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 29: Europe Macrolide Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 30: Europe Macrolide Antibiotics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 31: Europe Macrolide Antibiotics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 32: Asia Pacific Macrolide Antibiotics Market Value (USD billion), by Product, 2024 & 2032
  • Figure 33: Asia Pacific Macrolide Antibiotics Market Value Share (%), by Product, 2024
  • Figure 34: Asia Pacific Macrolide Antibiotics Market Value (USD billion), by Disease Indication, 2024 & 2032
  • Figure 35: Asia Pacific Macrolide Antibiotics Market Value Share (%), by Disease Indication, 2024
  • Figure 36: Asia Pacific Macrolide Antibiotics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 37: Asia Pacific Macrolide Antibiotics Market Value Share (%), by Route of Administration, 2024

2024 & 2032

  • Figure 38: Asia Pacific Macrolide Antibiotics Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 39: Asia Pacific Macrolide Antibiotics Market Value Share (%), by Age Group, 2024
  • Figure 40: Asia Pacific Macrolide Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 41: Asia Pacific Macrolide Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 42: Asia Pacific Macrolide Antibiotics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 43: Asia Pacific Macrolide Antibiotics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 44: Latin America Macrolide Antibiotics Market Value (USD billion), by Product, 2024 & 2032
  • Figure 45: Latin America Macrolide Antibiotics Market Value Share (%), by Product, 2024
  • Figure 46: Latin America Macrolide Antibiotics Market Value (USD billion), by Disease Indication, 2024 & 2032
  • Figure 47: Latin America Macrolide Antibiotics Market Value Share (%), by Disease Indication, 2024
  • Figure 48: Latin America Macrolide Antibiotics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 49: Latin America Macrolide Antibiotics Market Value Share (%), by Route of Administration, 2024

2024 & 2032

  • Figure 50: Latin America Macrolide Antibiotics Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 51: Latin America Macrolide Antibiotics Market Value Share (%), by Age Group, 2024
  • Figure 52: Latin America Macrolide Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 53: Latin America Macrolide Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 54: Latin America Macrolide Antibiotics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 55: Latin America Macrolide Antibiotics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 56: Middle East & Africa Macrolide Antibiotics Market Value (USD billion), by Product, 2024 & 2032
  • Figure 57: Middle East & Africa Macrolide Antibiotics Market Value Share (%), by Product, 2024
  • Figure 58: Middle East & Africa Macrolide Antibiotics Market Value (USD billion), by Disease Indication, 2024 & 2032
  • Figure 59: Middle East & Africa Macrolide Antibiotics Market Value Share (%), by Disease Indication, 2024
  • Figure 60: Middle East & Africa Macrolide Antibiotics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 61: Middle East & Africa Macrolide Antibiotics Market Value Share (%), by Route of Administration, 2024

2024 & 2032

  • Figure 62: Middle East & Africa Macrolide Antibiotics Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 63: Middle East & Africa Macrolide Antibiotics Market Value Share (%), by Age Group, 2024
  • Figure 64: Middle East & Africa Macrolide Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 65: Middle East & Africa Macrolide Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 66: Middle East & Africa Macrolide Antibiotics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 67: Middle East & Africa Macrolide Antibiotics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 68: Global Macrolide Antibiotics Market Share (%), By Company, 2024